Browsing by 저자 : 김상위
전체 결과 25건 중 1-25 번을 표시중입니다.
- 1 Article A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer 김상위 ; Benjamin C Creelan ; Don L Gibbons ; et al 2021
- 2 Article A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer 김상위 ; Benjamin C Creelan ; Don L Gibbons ; et al 2021
- 3 Article A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer 김상위 ; Ajlan Atasoy ; Charuwan Akewanlop ; et al 2021
- 4 Article A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer 강진형 ; 김동완 ; 김봉석 ; et al 2021
- 5 Article A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer 강진형 ; 김동완 ; 김봉석 ; et al 2021
- 6 Article Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study 김상위 ; Amy Roshak ; Byoung Chul Cho ; et al 2021
- 7 Article Blockade of CCL2 expression overcomes intrinsic PD-1/PD-L1 inhibitor-resistance in transglutaminase 2-induced PD-L1 positive triple negative breast cancer 공경엽 ; 김덕훈 ; 김상위 ; et al 2020
- 8 Article Clinical outcomes of nivolumab in patients with advanced non-small cell lung cancer in real-world practice, with an emphasis on hyper-progressive disease 김상위 ; 김수한 ; 김우성 ; et al 2020
- 9 Article Different prognostic implications of hepatic metastasis according to front-line treatment in non-small cell lung cancer: a real-world retrospective study 김상위 ; 김우성 ; 윤신교 ; et al 2021
- 10 Article Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations. 김상위 ; Agnieszka Cseh ; Christina Raabe ; et al 2021
- 11 Article Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer 김덕훈 ; 김상위 ; 윤신교 ; et al 2021
- 12 Article First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial 김상위 ; Adam Pluzanski ; Alain Vergnenegre ; et al 2021
- 13 Article Impact of pseudoprogression and treatment beyond progression on outcome in patients with non-small cell lung cancer treated with immune checkpoint inhibitors 원상은 ; 박효정 ; 변상일 ; et al 2020
- 14 Article Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung 김상위 ; 김우성 ; 윤신교 ; et al 2021
- 15 Article Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study 김상위 ; Anders Mellemgaard ; Byoung Chul Cho ; et al 2020
- 16 Article Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis 김상위 ; 김우성 ; 윤신교 ; et al 2020
- 17 Article Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC 김상위 ; Ajlan Atasoy ; Charuwan Akewanlop ; et al 2021
- 18 Article Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea 김상위 ; Bong-Seog Kim ; Byoung Chul Cho ; et al 2020
- 19 Article Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05. 김상위 ; 민영주 ; Byoung-Yong Shim ; et al 2021
- 20 Article Real-world use of osimertinib in non-small cell lung cancer: ASTRIS study Korean subgroup analysis 김상위 ; Byoung Chul Cho ; Cheol Hyeon Kim ; et al 2020
- 21 Article Real-world utility of next-generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma 김상위 ; 김좌훈 ; 윤신교 ; et al 2021
- 22 Article Recurrence-associated gene signature in patients with stage I non-small-cell lung cancer 김권일 ; 김상위 ; 윤신교 ; et al 2021
- 23 Article The NHance ® Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients 김상위 ; Ahmad Awada ; Alain Thibault ; et al 2021
- 24 Article Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial 김상위 ; Caicun Zhou ; Celina Griffin ; et al 2021
-
25
Research Laboratory
급성골수성 백혈병에서 CD34와 P-당단백의 발현
이제환
;
김우건
;
김상위
;
et al
1995
1